Kupffer Cell Necroptosis and Homeostatic Function in Liver Immune Responses against Ischemia Reperfusion Injury
库普弗细胞坏死性凋亡和肝脏缺血再灌注损伤免疫反应中的稳态功能
基本信息
- 批准号:9167747
- 负责人:
- 金额:$ 23.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-15 至 2018-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAnti-Inflammatory AgentsAnti-inflammatoryApoptoticCell DeathCell physiologyCellsClinicClinicalDataDichloromethylene DiphosphonateDimensionsDiseaseEmigrationsExcisionFoundationsFunctional disorderFutureHumanITGAM geneImmuneImmune responseIn VitroInfiltrationInflammationInflammatoryInflammatory InfiltrateInflammatory ResponseInjuryIschemiaKineticsKupffer CellsLiverMediatingModelingMolecularMusNecrosisOperative Surgical ProceduresOutcomePathogenesisPatternPattern recognition receptorPhagocytosisPlayProcessPublic HealthRecoveryReperfusion InjuryResearchResolutionRoleSeminalStagingTLR4 geneTestingTherapeuticTherapeutic InterventionTissuesTransplantationTraumaWarm Ischemiabasecell injurydesigndriving forceimmune activationimmune functionin vivoliver functionliver inflammationliver ischemiamacrophagemonocytenovelreceptorreconstitutionresearch studyresponsetargeted treatmenttumor
项目摘要
PROJECT SUMMARY
The overall object of our research in liver ischemia reperfusion injury (IRI) is to comprehend mechanisms of
inflammatory immune activation and resolution. In the last ten years, we have made significant progresses in
dissecting molecular mechanisms of liver innate immune response against IR. However, its cellular basis is
relatively less-well defined. Kupffer cells (KCs) are liver resident macrophages, which are highly
heterogeneous and evolving kinetically in disease processes. Their response against IR has not been fully
delineated, particularly in the context of recent finding that tissue resident and monocyte-derived infiltrating
macrophages are distinctive in their lineages and functions. Our recent analysis of KC/macrophage subsets in
IR livers reveals that liver inflammatory immune activation is associated with not only increases/activations of
infiltrating macrophages (iMØs), but also a drastic depletion of resident KCs (KCs). The opposite, i.e.,
contraction of iMØs and recovery of KCs, is associated with the resolution of liver inflammation. Additionally,
M1 polarization is evident in the activation stage, and M2 polarization in the resolution stage of liver immune
response in both liver macrophage subsets. The purpose of this exploratory project is to perform proof of
principle experiments to establish functional significance of KC depletion in liver IRI, and determine potential
mechanisms of KC homeostatic functions in livers against IR. We hypothesize that IR triggers KC
necroptosis which constitutes a key mechanism of liver inflammatory immune activation and functions
in synergy with the infiltration and activation of iMØs. Additionally, KCs execute the homeostatic
function in liver IRI by phagocytosis of apoptotic/necrotic cells, which regulates KC innate immune
activation and promotes their polarization towards immune regulatory/reparative type. We will test
these two hypothesis in two specific aims. Our study will be the first to analyze specifically responses and
functions of liver resident macrophages in IRI. Results will further our understanding of the disease
pathogenesis, and potentially provide novel rationale to design appropriate cell-targeted therapies to
ameliorate liver IRI.
项目摘要
我们研究肝脏缺血再灌注损伤(IRI)的总体目标是了解肝脏缺血再灌注损伤的机制。
炎症免疫激活和消退。在过去的十年里,我们在以下方面取得了重大进展:
解剖肝脏固有免疫反应的分子机制。然而,其细胞基础是
相对不太明确。枯否细胞(KCs)是肝脏驻留的巨噬细胞,其高度增殖。
在疾病过程中是异质的和动态进化的。他们对IR的反应还没有完全
描述,特别是在最近发现的背景下,组织驻留和单核细胞来源的浸润
巨噬细胞在它们的谱系和功能上是独特的。我们最近对KC/巨噬细胞亚群的分析表明,
IR肝脏显示肝脏炎症免疫激活不仅与肝脏炎症因子的增加/激活有关,
浸润性巨噬细胞(iMCs),但也急剧消耗常驻KC(KC)。相反,即,
iM的收缩和KC的恢复与肝脏炎症的消退相关。此外,本发明还
肝脏免疫激活期M1极化明显,消退期M2极化明显,
在两个肝巨噬细胞亚群中的反应。这个探索性项目的目的是证明
原则实验,以确定KC耗竭在肝脏IRI中的功能意义,并确定潜在的
KC的稳态功能在肝脏中对抗IR的机制。我们假设IR触发KC
坏死性凋亡构成肝脏炎症免疫激活和功能的关键机制
与iMIPs的渗透和激活协同作用。此外,KC执行稳态
通过吞噬凋亡/坏死细胞在肝脏IRI中发挥作用,调节KC先天免疫
激活并促进其向免疫调节/修复型极化。我们将测试
这两个假设有两个具体的目的。我们的研究将是第一个具体分析反应,
IRI中肝驻留巨噬细胞的功能。结果将进一步加深我们对这种疾病的了解
发病机制,并可能提供新的理论基础,设计适当的细胞靶向治疗,
改善肝脏IRI。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YUAN ZHAI其他文献
YUAN ZHAI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YUAN ZHAI', 18)}}的其他基金
Glycogen Synthase Kinase 3 beta in liver ischemia reperfusion injury
糖原合酶激酶3β在肝脏缺血再灌注损伤中的作用
- 批准号:
10721921 - 财政年份:2022
- 资助金额:
$ 23.1万 - 项目类别:
Glycogen Synthase Kinase 3 beta in liver ischemia reperfusion injury
糖原合酶激酶3β在肝脏缺血再灌注损伤中的作用
- 批准号:
10348751 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
Glycogen Synthase Kinase 3 beta in liver ischemia reperfusion injury
糖原合酶激酶3β在肝脏缺血再灌注损伤中的作用
- 批准号:
10153767 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
Regulation of Innate Immune Responses by Alloimmunity in Liver Ischemia-Reperfusion Injury
肝脏缺血再灌注损伤中同种免疫对先天免疫反应的调节
- 批准号:
9975699 - 财政年份:2017
- 资助金额:
$ 23.1万 - 项目类别:
Inflammation Resolution in Liver Ischemia-Reperfusion Injury
肝脏缺血再灌注损伤的炎症消退
- 批准号:
10622472 - 财政年份:2017
- 资助金额:
$ 23.1万 - 项目类别:
Inflammation Resolution in Liver Ischemia-Reperfusion Injury
肝脏缺血再灌注损伤的炎症消退
- 批准号:
10328214 - 财政年份:2017
- 资助金额:
$ 23.1万 - 项目类别:
CXCL10/CXCR3 Signaling Regulates TLR4-Mediated Liver Inflamation and Injury
CXCL10/CXCR3 信号传导调节 TLR4 介导的肝脏炎症和损伤
- 批准号:
7782845 - 财政年份:2010
- 资助金额:
$ 23.1万 - 项目类别:
CXCL10/CXCR3 Signaling Regulates TLR4-Mediated Liver Inflamation and Injury
CXCL10/CXCR3 信号传导调节 TLR4 介导的肝脏炎症和损伤
- 批准号:
8050656 - 财政年份:2010
- 资助金额:
$ 23.1万 - 项目类别:
CXCL10/CXCR3 Signaling Regulates TLR4-Mediated Liver Inflamation and Injury
CXCL10/CXCR3 信号传导调节 TLR4 介导的肝脏炎症和损伤
- 批准号:
8434152 - 财政年份:2010
- 资助金额:
$ 23.1万 - 项目类别:
CXCL10/CXCR3 Signaling Regulates TLR4-Mediated Liver Inflamation and Injury
CXCL10/CXCR3 信号传导调节 TLR4 介导的肝脏炎症和损伤
- 批准号:
8616058 - 财政年份:2010
- 资助金额:
$ 23.1万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 23.1万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 23.1万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 23.1万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 23.1万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 23.1万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 23.1万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 23.1万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 23.1万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 23.1万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 23.1万 - 项目类别:














{{item.name}}会员




